
<DOC>
<DOCNO>WT03-B24-167</DOCNO>
<DOCOLDNO>IA064-000378-B002-2</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/mitsubishi.html 206.86.52.80 19970112095058 text/html 8317
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:51:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8135
Last-modified: Sun, 12 May 1996 19:30:16 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Mitsubishi Chemical Corporation</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><H1>Mitsubishi Chemical Corporation</H1>
<H3>Corporate Profile</H3>
<HR>
2-24, Higashishinagawa 2-chome, Shinagawa-ku<BR>
Tokyo, Japan 140<BR>
Telephone: 81-3-5463-0721<BR>
Fax: 81-3-5463-0703<P>

<B>Employees:</B> 14,303<P>

Facilities:<BR>
<I>6 R&amp;D Centers:</I><BR>
<UL><LI> Yokohama
<LI> Yokkaichi
<LI> Tsukuba
<LI> Mizushima
<LI> Kashima
<LI> Kurosaki
</UL>
<I>10 Plants</I><BR>
<UL><LI> Kashima
<LI> Kurosaki
<LI> Yokkaichi
<LI> Naoetsu
<LI> Mizushima
<LI> Sakaide
<LI> Chigasaki
<LI> Tsukuba
<LI> Matsuyama
<LI> Odawara
</UL>
<I>39 Overseas</I><BR>

<I>Subsidiaries in 16 countries including:</I>
<UL><LI> Mitsubishi Chemical America, Inc. (Control of investment in North America; import/export business; manufacture /sales of products)<BR>
<LI> Seradyn, Inc. (Manufacture/sales of diagnostic equipment, reagents and quality analytical instruments)<BR>
<LI> Mitsubishi Chemical Europe GmbH (Import/Export business; liaison activities)<BR>
<LI> Mitsubishi Chemical (UK) Plc. (Clinical Research of Pharmaceuticals, Financing, Sales of Products)<P>
</UL>

<B>History</B>
<BLOCKQUOTE>Founded as Nippon-Tar Industries in 1934 as a chemical business unit of the  Mitsubishi Zaibatsu. In accordance with the Enterprise Readjustment and Reorganization Plan, the company restarted as Nihon Kasei Kogyo in 1950. Life Science Institute for basic life science research and Bioscience Laboratory for applied pharmaceutical R&amp;D were established in 1971. Pharmaceutical business started by the launch of Theodur&#174 in 1984. Mitsubishi Kasei Corp. acquired pharmaceutical R&amp;D of Mitsubishi Petrochemical Co. Ltd. in 1987. Pharmaceuticals and diagnostic company now exists as a inner company of Mitsubishi Chemical Corp.</BLOCKQUOTE><P>

<B>Established:</B> June, 1950<P>

<B>Subsidiaries (Pharmaceuticals and Diagnostic Companies)</B>
<UL>
<LI>Institute of Life Science</LI>
<LI>Institute of Toxicology and Environmental Science</LI>
<LI>Tokyo Tanabe Co., Ltd.</LI>
<LI>Dia Iatron Co., Ltd.</LI>
<LI>Seradyn, Inc.</LI>
<LI>Kasei Synthelabo</LI>
<LI>Yuka Medias, Co., Ltd.</LI></UL>

<B>Legal Form:</B> Public Corporation<P>

<B>Stock/Financial History</B><UL>
<LI>Offering, February, 1990, 140,631 (ten thousand stocks)</LI>
<LI>Stock split, May, 1991, 154,839 (ten thousand stocks)</LI>
<LI>Merger with Mitsubishi Petrochemical Co., 219,055 (ten thousand
stocks)</LI>
<LI>Total assets: 1426 billion yen</LI></UL><P>

<B>Investments:</B>
<UL><LI> Nikken Chemicals Co., Ltd.<BR>
<LI> Tokyo Tanabe Corporation, Ltd.<BR>
<LI> Kasei Synthelabo<P>
</UL>

<B>Private Placement<I>In domestic market:</B></I><BR>
<UL><LI> #15 issued in 2/26/90, 2 billion Yen<BR>
<LI> #11 issued in 6/28/94, 10
<LI> billion Yen<BR>
<LI> #12 issued in 6/28/94, 10 billion Yen<P>
</UL>

<I>In Euro-market:</I><BR>
<UL><LI> issued in 6/27/91, 3 billion Yen<BR>
<LI> issued in 2/18/94, 10 billion Yen<BR>
<LI> issued in 7/29/94, 10 billion Yen<P>
</UL>

<B>Principal Investors:</B><BR>
<UL><LI> The Meiji Mutual Life Insurance Co.<BR>
<LI> Nippon LifeInsurance Co.<BR>
<LI> The Mitsubishi Bank, Ltd.<P>
</UL>

<B>Corporate Overview</B><BR>
<BLOCKQUOTE>Mitsubishi Chemical Corporation (MCC) is a Japanese diversified chemical company heads more than 350 subsidiaries and affiliates in the group, which appears worldwide. MCC consists of 9 Business Groups or Inner Companies:<BR>
<UL><LI> Basic Petrochemicals Company
<LI> Industrial Chemicals Company
<LI> Polymer Products Company
<LI> Fiber Intermediates Company
<LI> Specialty Chemicals Company
<LI> Pharmaceuticals and  Diagnostic Company
<LI> Information and Electronics Company
<LI> Carbon and Agriculture Products Company
<LI> Functional Materials Company
</UL>

Our pharmaceuticals business activity are comprised of three main areas:  pharmaceuticals, diagnostic reagents and diagnostic instruments, and bulk substances and bovine serums. (Pharmaceuticals and diagnostic company) Pharmaceutical and Diagnostic Company in MCC orients a R&amp;D based pharmaceutical business unit. Total number of research and development employees is 650 including the Institute of Life Science. In pharmaceuticals area, MCC has succeeded in developing many new chemical entities for treating disorders of the central nervous system, cardiovascular system, immune system including allergies, and now MCC is making further efforts in medicinal research into disease affecting adults and the aged, in particular. In October 1993, MCC launched its 10th pharmaceutical product, a new anti-platelet aggregation agent Anplag&#174;. Sales of this product were consigned to Tokyo Tanabe Co., Ltd., and we expectthis company's annual sales of the product to reach YEN 10 billion. MCC also launched a new type of asthma medicine, Theodur&#174; Syrup, the world's first sustained release pediatric theophyillin syrup. We are engaged in developing our international business activities in positive manner. We have entered into business tie-ups with some pharmaceuticals companies in Europe and USA to establish the firm position abroad as well as at home. Our company is moving ahead with development of new medicines and expanding our  business activities from a global point of view.</BLOCKQUOTE>

<B>Technology Overview (Pharmaceuticals and Diagnostic Company)</B>
<BLOCKQUOTE>Following Theodur&#174;, sustained-release anti-asthma drug, MCC introduced a variety of pharmaceuticals, including Romet&#174;, an anti-allergic agent, Alnert&#174;, anti-thrombotic agent, Novastan, the t-PA Grtpa&#174; and Hepatitis-B vaccine Mitsubishi&#174;. Novastan&#174; was developed using MCC's molecular design technique, making it the first anti-thrombotic agent in the world. GRTPA&#174; and Hepatitis-B vaccine Mitsubishi&#174; are new type drugs developed using gene-recombinant technology. MCC has launched its anti-platelet agent, Anplag&#174; and anti-rheumatic agent, Mover&#174;.</BLOCKQUOTE><P>

<B>Agreements (Pharmaceuticals and Diagnostic Company)</B><BR>
<I>Licensing Agreements</I><BR>
<UL><LI> Genentech
<LI> Merz
<LI> Synthelabo
<LI> Schering Plough<P>
<I>Corporation Agreement</I><BR>
<UL><LI> ASTRA
<LI> MMD
</UL>
</UL><P>

<B>Products on Market:</B>
 Theodur&#174;, Myse&#174;, Romet&#174;, Alnert&#174;, Celeport&#174;, Vasomet&#174;, Novastan&#174;, Slonnon, Grtpa&#174;, r-HB Vaccine&#174;, Kerlong&#174;, Anplag&#174;, Mover&#174;, CRH<P>

<B>Products in R&amp;D<</B>P>
15 products under clinical evaluation and 5 products in preclinical stage<P>

<B>Current Corporate Partners</B><UL>
<LI>ASTRA</LI>
<LI>MMD</LI></UL>

<B>Management:</B><BR>
Masahiko Furukawa, Chairman of the Board<BR>
President: Akira Miura<P>

<B>Managing Directors:</B><BR>
Hideo Fukutani, Yousuke Ariyoshi, Keiichi Higuchi, Takashi Saito,
Naotoki Sawada, Takeo Okunishi, Yasuo Harada, Hiroshi Imada, Kanji
Shono, Arata Makino, Takeru Onoda, Morihisa Takano, Tsuyoshi Yamamoto, Shoei Yokoyama, Hideo Watanabe, Yoshimichi Nakamura, Yoshihisa Narukawa<P>

<B>Board of Directors:</B> J.L.Stitt, Ichiro Kagawa, Muneo Suzuki,
Kohsuke Kanaya, Masatoshi Shimosaka, Takayori Tsuboi, Teruo Kobori,
Junichi Yamaguchi, Takehiko Sugasawa, Kazuhiro Matsui, Norihiko
Nishiyama, Yuichi Matsumoto, Kiyoshi Sasaki, Tetsuo Komuro, Yoshimi
Shibata, Masaaki Nishikawa, Yoshitoshi Tsunoda, Kouji Matsuda, Masanori Namikawa, Keisuke Mizukami, Toshihiko Aritake, Tadashi Ohira, Mitsuo Sagara, Koichiro Maekawa, Yoshihisa Shoda, Masamitsu Odagiri, Kizo Yamada, Kenichi Yoshimi, Eiichi Ono, Mitsuyoshi Mitsuoka<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated June 16, 1995.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>
<!-- revised Saturday, June 3, 1995 4:55AM >

<!-- Subject Terms:
Senile dementia, Schizaphrenia, Arrhythmia, Hyperlipidemia,
Hypertension, Gastro intestinal disorders, Asthma, Rhinitis, Allergic dermatological diseases, Diabetes, Bone diseases, Imaging.<P> >
</DOC>